Why Does Illumina Want to Reunite With Grail?
Five years ago, Illumina (NASDAQ: ILMN) created Grail, a liquid biopsy biotech that hopes to detect as many as 50 types of cancers with a single blood draw from patients. In 2017, Illumina spun out Grail as a separate entity, while keeping a minority stake. Grail was all set for its initial public offering when Illumina made an $8 billion offer to reacquire the company.
Why is Illumina trying to buy its former subsidiary? And why are regulators trying to quash the deal? In a video recorded live on July 30, Olivia Zitkus, an editor and analyst at Fool.com, and Motley Fool writer Taylor Carmichael discuss Illumina and Grail.
Source Fool.com
